Further validation of CCL8, CXCL13, and IL-1RA as biomarkers in SLE across multiple cohorts and diverse populations is warranted, as is standardisation of their quantification and establishment of appropriate cut-offs. Here, CXCL13 is linked to systemic lupus erythematosus.